Rockefeller Capital Management L.P. Uni Qure N.V. Transaction History

Rockefeller Capital Management L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	SELL	$18.12 - $27.32 $326 - $491	-18 Reduced 11.46%	139 $3,000
Q3 2022 Nov 02, 2022	SELL	$16.98 - $25.54 $3,752 - $5,644	-221 Reduced 58.47%	157 $2,000
Q2 2022 Aug 12, 2022	BUY	$13.15 - $20.45 $3,037 - $4,723	231 Added 157.14%	378 $6,000
Q1 2022 May 13, 2022	BUY	$14.54 - $21.5 $1,061 - $1,569	73 Added 98.65%	147 $1,000
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $24,814 - $44,148	-1,226 Reduced 94.31%	74 $0
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $33,813 - $49,686	1,300 New	1,300 $41,000
Q3 2019 Nov 12, 2019	SELL	$39.36 - $76.8 $39,241 - $76,569	-997 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$52.76 - $82.19 $52,601 - $81,943	997 New	997 $78,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.